文献速递垂体与肾上腺疾病

靶向CRH受体的分子影像用于促肾上腺皮质激素瘤:范式转变

Molecular Imaging Targeting Corticotropin-releasing Hormone Receptor for Corticotropinoma: A Changing Paradigm.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

研究纳入27例ACTH依赖性库欣综合征患者(24例库欣病,3例异位CS),行68Ga CRH PET-CT并融合MRI。68Ga CRH PET-CT正确勾画全部24例促肾上腺皮质激素瘤,包括10例<6mm(4例MRI阴性),且与术中所见及病理一致;2例异位CS垂体无摄取。提示该分子影像可定位肿瘤并鉴别ACTH来源。

要点

  • 68Ga CRH PET-CT可勾画促肾上腺皮质激素瘤,包括MRI阴性微腺瘤
  • 融合MRI可用于术中导航,定位与手术及病理一致
  • 异位CS垂体无摄取,有助鉴别ACTH来源

核心结论

  • 68Ga CRH PET-CT靶向CRH受体,可无创勾画促肾上腺皮质激素瘤并辅助鉴别垂体与垂体外ACTH来源。

研究设计与样本

  • 研究纳入27例ACTH依赖性库欣综合征患者,其中库欣病24例、异位CS 3例,行68Ga CRH PET-CT,两名核医学医师读图并与MRI鞍区融合。

主要发现

  • 68Ga CRH PET-CT正确勾画全部24例库欣病的促肾上腺皮质激素瘤,包括10例腺瘤<6mm(其中4例MRI阴性)。
  • 融合图像上肿瘤位置与术中所见一致,并经组织病理学确认。
  • 2例异位CS患者垂体无示踪剂摄取,另1例垂体弥漫摄取提示异位CRH产生。

临床怎么用

  • 对ACTH依赖性库欣综合征,68Ga CRH PET-CT融合MRI可辅助促肾上腺皮质激素瘤定位与术中导航。
  • 垂体无摄取而临床疑异位CS时,该影像有助提示垂体外ACTH来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Corticotrophin-releasing hormone (CRH) is the major regulator of adrenocorticotrophic hormone (ACTH) secretion from the anterior pituitary and acts via CRH-1 receptors (CRH-1R). Corticotropinoma though autonomous, still retain their responsiveness to CRH and hence, we hypothesize that in vivo detection of CRH-1 receptors on pituitary adenoma using Gallium-68 (68Ga)-tagged CRH can indicate the functionality of adenoma, and combining it with positron emission tomography-computed tomography (PET-CT) can provide requisite anatomical information. METHODS: Subjects with ACTH-dependent Cushing's syndrome (CS) (n = 27, 24 with Cushing's disease [CD], 3 with ectopic CS [ECS]) underwent 68Ga CRH PET-CT. Two nuclear medicine physicians read these images for adenoma delineation and superimposed them on magnetic resonance imaging (MRI) sella. The information provided was used for intraoperative navigation and compared with operative and histopathological findings. FINDINGS: 68Ga CRH PET-CT correctly delineated corticotropinoma in all the 24 cases of CD, including the 10 cases with adenoma size < 6mm (4 cases were negative on MRI). Corticotropinoma location on 68Ga CRH PET fusion images with MRI were concordant with operative findings and were further confirmed on histopathology. There was no tracer uptake in the pituitary in 2 patients with ECS, while, in another, the diffuse uptake in pituitary suggested ectopic CRH production. CONCLUSION: 68Ga CRH PET-CT represents a novel, noninvasive molecular imaging, targeting CRH receptors that not only delineate corticotropinoma and provides the surgeon with valuable information for intraoperative tumor navigation, but also helps in differentiating a pituitary from an extra-pituitary source of ACTH-dependent CS. FUNDING: None.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Walia R, Gupta R, Bhansali A, et al. Molecular Imaging Targeting Corticotropin-releasing Hormone Receptor for Corticotropinoma: A Changing Paradigm. J Clin Endocrinol Metab. 2021. PMID: 33079979. doi:10.1210/clinem/dgaa755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。